The latest price target for Intellia Therapeutics (NASDAQ:NTLA) was reported by Canaccord Genuity on June 16, 2026. The analyst firm set a price target for $49.00 expecting NTLA to rise to within 12 months (a possible 213.50% upside). 53 analyst firms have reported ratings in the last year.

The latest analyst rating for Intellia Therapeutics (NASDAQ:NTLA) was provided by Canaccord Genuity, and Intellia Therapeutics maintained their buy rating.

The last upgrade for Intellia Therapeutics Inc happened on March 4, 2026 when Jones Trading raised their price target to $29. Jones Trading previously had a hold for Intellia Therapeutics Inc.

The last downgrade for Intellia Therapeutics Inc happened on November 12, 2025 when Wolfe Research changed their price target from N/A to N/A for Intellia Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on June 16, 2026 so you should expect the next rating to be made available sometime around June 16, 2027.

While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a maintained with a price target of $49.00 to $49.00. The current price Intellia Therapeutics (NTLA) is trading at is $15.63, which is out of the analyst’s predicted range.